GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Europe and the Asia Pacific. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
IPO Year:
Exchange: NASDAQ
Website: https://www.glucotrack.com
Rutherford, NJ and Or Yehuda, Israel, March 14, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (NASDAQ:GCTK) ("GlucoTrack" or the "Company"), formerly known as Integrity Applications, Inc., (NASDAQ:IGAP), innovator of GlucoTrack®, a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that it has completed its corporate name and ticker symbol change on the Nasdaq Capital Market, to be effective at the commencement of trading today, March 14, 2022.
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.6% to $1.35 during Friday's regular session. As of 12:30 EST, Dermata Therapeutics's stock is trading at a volume of 17.7 million, which is 7371.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $11.2 million. Vaccinex (NASDAQ:VCNX) stock moved upwards by 22.43% to $1.91. Trading volume for Vaccinex's stock is 6.4 million as of 12:30 EST. This is 588.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $75.5 million. Oak Street Health (NYSE:OSH) shares increased by 15.41% to $19.32. The current volume
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.1% to $1.35 during Thursday's regular session. The current volume of 17.5 million shares is 7266.3% of Dermata Therapeutics's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $11.2 million. Vaccinex (NASDAQ:VCNX) shares increased by 20.53% to $1.88. As of 12:30 EST, Vaccinex's stock is trading at a volume of 6.1 million, which is 560.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $74.3 million. Oak Street Health (NYSE:OSH) stock moved upwards by 15.02% to $19.25. Trading volume for Oak Street
Check out these penny stocks insiders are buying ToughBuilt Industries, Inc. (NASDAQ:TBLT) rose 17.6% to close at $0.2863. Virgin Orbit Holdings, Inc. (NASDAQ:VORB) climbed 17.5% to close at $7.99 after dropping 18% on Monday. Dermata Therapeutics, Inc. (NASDAQ:DRMA) surged 17.1% to close at $1.99. Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) rose 16% to close at $20.28. Allscripts Healthcare Solutions expects Q4 revenue of $390 million - $395 million, better than the consensus of $$386.75 million. SVB Leerink upgraded Allscripts Healthcare from Market Perform to Outperform and raised the price target from $19 to $22. Turquoise Hill Resources Ltd. (NYSE:TRQ) shares gained 15.9% t
To begin trading under the Nasdaq Symbol GCTK Rutherford, NJ and Or Yehuda, Israel, March 14, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (NASDAQ:GCTK) ("GlucoTrack" or the "Company"), formerly known as Integrity Applications, Inc., (NASDAQ:IGAP), innovator of GlucoTrack®, a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that it has completed its corporate name and ticker symbol change on the Nasdaq Capital Market, to be effective at the commencement of trading today, March 14, 2022. The corporate name change and ticker symbol change do not affect the rights of the Company's stockholders nor the n
Wilmington, DE and Or Yehuda, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. (www.integrity-app.com) (NASDAQ:IGAP), innovator of GlucoTrack®, a non-invasive device for measuring glucose levels in people with Type II diabetes and prediabetes announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a message and year-to-date shareholder update letter. To our valued shareholders: On November 1st, I stepped down from my position on the board to become President and Chief Operating Officer of the company. In connection with our Nasdaq listing, I was asked to take on the role of Chief Executive Officer, to be effective today, a r